Integrating Biospecimen Science Approaches into Clinical Assay Development (U01 Clinical Trial Not Allowed)
ID: 357712Type: Posted
Overview

Buyer

National Institutes of Health (HHS-NIH11)

Eligible Applicants

Others

Funding Category

Health

Funding Instrument

Cooperative Agreement

Opportunity Category

Discretionary

Cost Sharing or Matching Requirement

Yes

Original Source

https://grants.gov/search-results-detail/357712

Additional Information

http://grants.nih.gov/grants/guide/pa-files/PAR-25-325.html
Timeline
    Description

    The National Institutes of Health (NIH), through the National Cancer Institute (NCI), has announced a funding opportunity titled "Integrating Biospecimen Science Approaches into Clinical Assay Development" (FON: PAR-25-325). This initiative aims to support extramural research focused on addressing preanalytical variability in the development and analytical validation of clinical assays utilizing biospecimens such as tumor biopsies and liquid biopsies. The program seeks to enhance the reliability of biomarker assays by investigating how various collection, processing, and storage conditions impact biomarker quantification, ultimately contributing to improved cancer diagnostics and treatment in precision medicine. Interested applicants can apply for funding of up to $250,000 annually for a period of five years, with the first application deadline set for January 4, 2025. For further inquiries, applicants may contact NIH Grants Information at grantsinfo@nih.gov or visit the additional information link at https://grants.nih.gov/grants/guide/pa-files/PAR-25-325.html.

    Point(s) of Contact
    grantsinfo@nih.gov
    Files
    Title
    Posted
    PAR-25-325-Full-Announcement.html
    PAR-25-325.html
    The National Cancer Institute (NCI) under the Department of Health and Human Services announces a funding opportunity titled "Integrating Biospecimen Science Approaches into Clinical Assay Development" (FON: PAR-25-325). This initiative aims to support extramural research focused on addressing preanalytical variability in the development and analytical validation of clinical assays utilizing biospecimens like tumor biopsies and liquid biopsies. Researchers are invited to investigate how collection, processing, and storage conditions impact biomarker reliability, aiming to standardize practices that enhance biomarker assay development. Key submission dates include application deadlines starting from January 4, 2025, with funding available for five years and budgets capped at $250,000 annually. Eligible applicants include educational institutions, non-profits, and government agencies, with encouragement for diverse and underrepresented individuals in research roles. The NCI emphasizes an integrated, multidisciplinary approach involving various scientific and medical disciplines to optimize biomarker assays for clinical trials. Overall, the initiative seeks to improve cancer diagnostics and treatment through enhanced biomarker validation, thus contributing significantly to precision medicine in oncology.
    Similar Opportunities
    Loading similar opportunities...